Ira Gupta

4.5k total citations
76 papers, 2.0k citations indexed

About

Ira Gupta is a scholar working on Hematology, Genetics and Pathology and Forensic Medicine. According to data from OpenAlex, Ira Gupta has authored 76 papers receiving a total of 2.0k indexed citations (citations by other indexed papers that have themselves been cited), including 40 papers in Hematology, 34 papers in Genetics and 29 papers in Pathology and Forensic Medicine. Recurrent topics in Ira Gupta's work include Chronic Lymphocytic Leukemia Research (33 papers), Multiple Myeloma Research and Treatments (32 papers) and Lymphoma Diagnosis and Treatment (29 papers). Ira Gupta is often cited by papers focused on Chronic Lymphocytic Leukemia Research (33 papers), Multiple Myeloma Research and Treatments (32 papers) and Lymphoma Diagnosis and Treatment (29 papers). Ira Gupta collaborates with scholars based in United States, United Kingdom and Germany. Ira Gupta's co-authors include Steen Lisby, Roxanne C. Jewell, Rainer Lüdtke, Hasan Safayhi, S. Gupta, Gupta, Swaminathan P. Iyer, Joanna Opalinska, William G. Wierda and Rakesh Popat and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer.

In The Last Decade

Ira Gupta

74 papers receiving 1.9k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Ira Gupta United States	23	870	753	719	717	639	76	2.0k
Vincenzo Callea Italy	26	1.3k 1.5×	797 1.1×	771 1.1×	630 0.9×	1.1k 1.7×	85	2.2k
Aleksander B. Skotnicki Poland	20	856 1.0×	461 0.6×	1.2k 1.6×	792 1.1×	493 0.8×	130	2.3k
Kena C. Miller United States	18	696 0.8×	468 0.6×	636 0.9×	506 0.7×	615 1.0×	69	1.4k
Donna M. Weber United States	28	2.7k 3.1×	1.6k 2.1×	616 0.9×	413 0.6×	2.4k 3.7×	132	3.6k
Dixie Esseltine United States	22	1.9k 2.1×	1.6k 2.2×	539 0.7×	506 0.7×	1.8k 2.8×	44	3.1k
Giulia Perrone Italy	20	1.5k 1.7×	1.2k 1.5×	248 0.3×	207 0.3×	1.3k 2.0×	53	2.4k
William Deraedt United States	15	2.2k 2.6×	1.5k 2.1×	410 0.6×	199 0.3×	1.7k 2.7×	56	2.7k
Jacques‐Louis Binet France	12	330 0.4×	277 0.4×	1.3k 1.8×	1.1k 1.6×	223 0.3×	21	1.8k
María Teresa Cibeira Spain	23	1.3k 1.4×	709 0.9×	398 0.6×	105 0.1×	1.3k 2.1×	91	2.0k
Florence Cymbalista France	20	461 0.5×	341 0.5×	1.3k 1.8×	960 1.3×	303 0.5×	82	1.7k

Countries citing papers authored by Ira Gupta

Since Specialization

Citations

This map shows the geographic impact of Ira Gupta's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ira Gupta with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ira Gupta more than expected).

Fields of papers citing papers by Ira Gupta

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ira Gupta. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ira Gupta. The network helps show where Ira Gupta may publish in the future.

Co-authorship network of co-authors of Ira Gupta

This figure shows the co-authorship network connecting the top 25 collaborators of Ira Gupta. A scholar is included among the top collaborators of Ira Gupta based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ira Gupta. Ira Gupta is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Patnaik, Mrinal M., Haris Ali, Eunice S. Wang, et al.. (2025). Tagraxofusp, a CD123-targeted therapy, for chronic myelomonocytic leukemia: final results of a phase 1/2 study. PubMed. 2(4). 100115–100115.

Pemmaraju, Naveen, Marina Konopleva, Kendra Sweet, et al.. (2025). Efficacy of first-line tagraxofusp in blastic plasmacytoid dendritic cell neoplasm with prior or concomitant hematologic malignancy: subgroup analysis of a pivotal trial. Leukemia & lymphoma. 66(7). 1342–1345.

Konopleva, Marina, Naveen Pemmaraju, Kendra Sweet, et al.. (2024). Tagraxofusp Achieves Anti-Tumor Activity with Rapid Restoration of Normal Hematopoiesis in Treatment-Naïve Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): Subanalysis of a Pivotal Trial. Blood. 144(Supplement 1). 1515–1515. 2 indexed citations

Aggarwal, Priyanka, et al.. (2024). Unraveling the Complex Relationship—Atrial Fibrillation and Pulmonary Hypertension. Current Cardiology Reports. 26(9). 885–891. 1 indexed citations

Daver, Naval, Naveen Pemmaraju, Mikkael A. Sekeres, et al.. (2024). Phase 2 Multicenter Trial of Tagraxofusp in Combination with Venetoclax and Azacitidine in Adults with Previously Untreated CD123+ Acute Myeloid Leukemia Ineligible for Intensive Chemotherapy. Blood. 144(Supplement 1). 4265.1–4265.1. 1 indexed citations

Iida, Shinsuke, et al.. (2023). Safety, pharmacokinetics, and efficacy of belantamab mafodotin monotherapy in Japanese patients with relapsed or refractory multiple myeloma: DREAMM-11. International Journal of Hematology. 118(5). 596–608. 3 indexed citations

Popat, Rakesh, Sagar Lonial, Peter M. Voorhees, et al.. (2023). Patient-Reported Outcomes With Belantamab Mafodotin Treatment in Patients With Triple-Class Refractory Multiple Myeloma. Journal of the Advanced Practitioner in Oncology. 14(6). 503–518. 3 indexed citations

Lonial, Sagar, Ajay K. Nooka, Praneetha Thulasi, et al.. (2021). Management of belantamab mafodotin-associated corneal events in patients with relapsed or refractory multiple myeloma (RRMM). Blood Cancer Journal. 11(5). 103–103. 47 indexed citations

Farooq, Asim V., Simona Degli Esposti, Rakesh Popat, et al.. (2020). Corneal Epithelial Findings in Patients with Multiple Myeloma Treated with Antibody–Drug Conjugate Belantamab Mafodotin in the Pivotal, Randomized, DREAMM-2 Study. Ophthalmology and Therapy. 9(4). 889–911. 109 indexed citations

10.

Richardson, Paul G., Hans C. Lee, Adam D. Cohen, et al.. (2020). Single-agent belantamab mafodotin for relapsed/refractory multiple myeloma: analysis of the lyophilised presentation cohort from the pivotal DREAMM-2 study. Blood Cancer Journal. 10(10). 106–106. 40 indexed citations

11.

Popat, Rakesh, Asim V. Farooq, Praneetha Thulasi, et al.. (2020). Ocular Health of Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Baseline Data from the DREAMM-2 Trial of Belantamab Mafodotin (Belamaf). Blood. 136(Supplement 1). 43–44. 2 indexed citations

12.

Trudel, Suzanne, Nikoletta Lendvai, Rakesh Popat, et al.. (2019). Antibody–drug conjugate, GSK2857916, in relapsed/refractory multiple myeloma: an update on safety and efficacy from dose expansion phase I study. Blood Cancer Journal. 9(4). 37–37. 171 indexed citations

13.

Stein, Eytan M., Richard M. Stone, Daniel A. Pollyea, et al.. (2017). Continuing Enasidenib Treatment for Patients with Mutant- IDH2 (m IDH2) Relapsed or Refractory Acute Myeloid Leukemia (R/R AML) with Stable Disease May Result in Improved Survival and Responses over Time. Blood. 130. 1299–1299. 2 indexed citations

14.

Österborg, Anders, Andrey Zaritskey, Sebastian Grosicki, et al.. (2016). Phase III, randomized study of ofatumumab versus physicians’ choice of therapy and standard versus extended-length ofatumumab in patients with bulky fludarabine-refractory chronic lymphocytic leukemia. Leukemia & lymphoma. 57(9). 2037–2046. 20 indexed citations

15.

Robak, Tadeusz, Sebastian Grosicki, Krzysztof Warzocha, et al.. (2015). Ofatumumab (O) in combination with fludarabine (F) and cyclophosphamide (C) (OFC) vs. FC in patients with relapsed chronic lymphocytic leukaemia (CLL): results of the phase III study complement 2. Haematologica. 100. 3 indexed citations

16.

Oers, Marinus H. J. van, Kazimierz Kuliczkowski, Lukáš Smolej, et al.. (2015). Ofatumumab maintenance versus observation in relapsed chronic lymphocytic leukaemia (PROLONG): an open-label, multicentre, randomised phase 3 study. The Lancet Oncology. 16(13). 1370–1379. 84 indexed citations

17.

Hillmen, Peter, Tadeusz Robak, Ann Janssens, et al.. (2013). Ofatumumab + Chlorambucil Versus Chlorambucil Alone In Patients With Untreated Chronic Lymphocytic Leukemia (CLL): Results Of The Phase III Study Complement 1 (OMB110911). Blood. 122(21). 528–528. 58 indexed citations

18.

Gupta, Ira & Roxanne C. Jewell. (2012). Ofatumumab, the first human anti‐CD20 monoclonal antibody for the treatment of B cell hematologic malignancies. Annals of the New York Academy of Sciences. 1263(1). 43–56. 37 indexed citations

19.

Wierda, William G., Thomas J. Kipps, Jan Dürig, et al.. (2011). Chemoimmunotherapy with O-FC in previously untreated patients with chronic lymphocytic leukemia. Blood. 117(24). 6450–6458. 86 indexed citations

20.

Wierda, William G., Thomas J. Kipps, Jan Dürig, et al.. (2009). Ofatumumab Combined with Fludarabine and Cyclophosphamide (O-FC) Shows High Activity in Patients with Previously Untreated Chronic Lymphocytic Leukemia (CLL): Results From a Randomized, Multicenter, International, Two-Dose, Parallel Group, Phase II Trial.. Blood. 114(22). 207–207. 21 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact